Brief: Daxor Corporation Streamlines Regulatory Strategy For Groundbreaking Diagnostic Device
27/09/2024 22:19
Sept 27 (Reuters) - Daxor Corp DXR.O :
* DAXOR CORPORATION STREAMLINES REGULATORY STRATEGY FOR
GROUNDBREAKING DIAGNOSTIC DEVICE
* DAXOR CORP - TO WITHDRAW DUAL 510(K)/CLIA-WAIVER
APPLICATION
* DAXOR CORP - TO SUBMIT NEW 510(K) APPLICATION NEXT QUARTER
* DAXOR CORP - TO PURSUE SEPARATE CLIA-WAIVER APPLICATION
Source text for Eikon: ID:nGNX6pc59P
Further company coverage: DXR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Daxor
See all newsNASDAQ RESUMED AT 02:03 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:58 PM
Brief: Daxor Corp Reaffirms Focus On Blood Volume Analysis Technology
Brief: Daxor Corporation Submits 510(K) To FDA For Next-Generation Blood Volume Analyzer
Brief: Daxor Corporation Streamlines Regulatory Strategy For Groundbreaking Diagnostic Device